We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Recruiting
100.0%
No approval data available
- University of Geneva researchers have created a revolutionary DNA-based drug delivery system that uses computer-like logic to target cancer cells with unprecedented precision. - The system employs a "two-factor authentication" approach, requiring both cancer markers to be present before activating the drug, significantly reducing damage to healthy cells. - Unlike traditional antibody-drug conjugates, the smaller DNA strands can penetrate tumors more effectively and carry multiple drug components simultaneously. - The technology represents a breakthrough in programmable medicine, with drugs that can "compute" and respond intelligently to biological signals within the body.